Christine Blank

Most private health insurance plans are required to cover vaccines for COVID-19 without patient cost-sharing.

Results for Amgen’s Blincyto (blinatumomab) suggest it has efficacy as a treatment for Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

Researcher modeling the cost effectiveness of chimeric antigen receptor T-cell therapy (CAR-T) therapy and antibody conjugate found that they fell short.

The Covid-19 pandemic revealed the advantages of treatment that involved fewer in-person office visits, according to research presented at American Society of Hematology meeting earlier this month. Researchers also saw a notable increase in the use of Darzalex (daratumumab).

Johnson & Johnson’s Tecvayli (teclistamab-cqyv) has been approved by the FDA, and Pfizer’s elranatamab received breakthrough status that should speed its approval. Bispecific antibodies may be a bridge to CAR-T treatments or an alternative to them.

Positive results for Adcetris (brentuximab vedotin) were reported in The New England Journal of Medicine. Further research will include a look at the cost effectiveness of Adcetris.

Durability and toxicities such as cytokine release syndrome and immune effector-cell neurotoxicity syndrome are among the challenges.

The study looked at cancer patients as a group, but senior author notes that ‘that treatments for blood cancers are very costly and many of them require treatment for long periods of time.’

Findings may support the development of an aerobic exercise training intervention for people with multiple sclerosis (MS) who present with MS-related thalamic atrophy.

Research conducted in Canada suggests that people with multiple sclerosis would benefit from being seen by nurse practitioners. However, secondary outcomes in the study did not improve among patients with access to nurse practitioner-led care.

The researchers attributed low adherence to oral anti-cancer medications for blood cancer and certain other cancers to high monthly out-of-pocket among several other reasons.

Researchers report that half of the online pharmacies are rogue operations that may operate without a license or have other serious shortcomings.

Violaine Harris, Ph.D., a senior research scientist with Tisch MS Research Center of New York, discusses new research that shows stem cell treatments can improve disability in patients with MS.

This is the first study to examine the effects of vibration training on changing cognition and quality of life in people with multiple sclerosis.

The lack of biomarkers for progressive multiple sclerosis has made the development of new treatments much more difficult for this form of the disease.

A study in mice has found that a combination immunotherapy slowed tumor growth and activated anti-tumor immune response.

Researchers stress that attention to cardiac risk intervention is warranted for lean patients with nonalcoholic fatty liver disease (NAFLD)

Anthony Feinstein, Ph.D., of the University of Toronto, author of a new book about multiple sclerosis and mood, says clinicians and patients need to pay more attention to the effects that depression has on the cognitive abilities of patients with the disease.

Study in Czech Republic followed 392 patients for approximately four years.

Blood-based biomarker test can be used to assess disease activity in patients with multiple sclerosis and for treatment response monitoring.

An animal study of histotripsy suggests that powerful, focused ultrasound might be a way of treating liver cancer. It is a preliminary study. Much more research will need to be done before the technology is accepted as safe and effective.

The goal is to screen 20,000 people in the U.S. with at-home genetic tests for nonalcoholic fatty liver disease (NAFLD).

Review of 28 studies suggests role for CBD and THC as therapy for MS but evidence base needs to be stronger.

Researchers say kappa free light chain tests would be less costly and produce results sooner than the oligoclonal band tests.

The prevalence of nonalcoholic fatty liver disease (NAFLD) is significantly higher in men (33%) than women (20%).

The interplay between nonalcoholic fatty liver disease and diabetes can amplify both conditions, say two prominent researchers.

German research team finds that 11% of those who quit the drug for pregnancy had “clinically meaningful disability” one-year postpartum. They don’t advise against quitting the drug but say their findings suggest that patients should be informed of the risk.

Results of an AstraZeneca trial presented at a recent ASCO meeting sow hopes for a new treatment for patients diagnosed with unresectable hepatocellular carcinoma, the most common type of liver cancer.

'Just do it' is the takeaway from a review of 19 studies that found no difference between bouts of high-intensity physical activity and more moderate forms of aerobic exercise when it comes reducing liver fat.

The composition of the microbiota of the airways of people with chronic obstructive pulmonary disorder explains varying degrees of inflammation, according to a review article published recently in the Annals of Medicine.